SEC Form 4 · accession 0001553878-17-000002
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Maraganore
Officer — Chief Executive Officer · Director
Period of report
Jan 5, 2017
Accepted (ET)
Jan 6, 2017 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 5, 2017 | M | 1,340 | $18.66 | A | 149,710 | D | |
| Common StockF1 | holding | — | — | — | 2,841 | I | By Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $18.66 | Jan 5, 2017 | M | 1,340 | D | — | Dec 20, 2022 | Common Stock | 1,340 | 144,641 | D |
Explanation of responses
- F1The reporting person owns 2,841 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F2The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.